Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 12/20 | 0.66 |
| ▸ | NFE2L2 | Q16236 | 12/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.57 |
| ▸ | OXTR | P30559 | 1/20 | 0.55 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1629270 | 0.89 | NR1I2 (0.57) | KEAP1NFE2L2PGROXTRAVPR1A | |
| SCHEMBL1630949 | 0.85 | KEAP1 (0.87) | KEAP1NFE2L2MAPTTP53 | |
| SCHEMBL1630148 | 0.85 | HCRTR2 (0.61) | KEAP1NFE2L2PGROXTRAVPR1A | |
| SCHEMBL1632612 | 0.84 | HCRTR2 (0.61) | KEAP1NFE2L2OXTR | |
| SCHEMBL1629149 | 0.81 | HCRTR2 (0.58) | KEAP1NFE2L2OXTR | |
| SCHEMBL27910116 | 0.81 | BMP1 (0.58) | KEAP1NFE2L2PGROXTRAVPR1A | |
| SCHEMBL1629905 | 0.79 | KEAP1 (0.76) | KEAP1NFE2L2 | |
| SCHEMBL1630305 | 0.79 | KEAP1 (0.71) | KEAP1NFE2L2PGROXTRMAPT | |
| SCHEMBL1629157 | 0.79 | KEAP1 (0.70) | KEAP1NFE2L2 | |
| SCHEMBL1629052 | 0.78 | HTT (0.49) | KEAP1NFE2L2PGROXTRAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245006-B1 | SULFONAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-01 | — | — | EP | disclosed |
| EP-2245006-B1 | SULFONAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-01 | — | — | EP | disclosed |
| US-7932269-B2 | Sulfonamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932269-B2 | Sulfonamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932269-B2 | Sulfonamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2245006-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009092642-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009092642-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-30 | — | — | WO | disclosed |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | KEAP1 1802/4885NFE2L2 1690/4885PGR 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.